{"entity":{"id":"lmy-920","kind":"drug","name":"LMY-920","aka":["BAFF CAR-T","BAFF-L CAR T cells"],"tldr":"LMY-920 is an experimental CAR-T treatment from Luminary Therapeutics, made from a patient's own immune cells, aimed at three receptors on cancerous B cells. It is in early trials in lymphoma and myeloma.","summary":"LMY-920 is a BAFF ligand-based CAR-T cell therapy developed by Luminary Therapeutics. Two phase 1 trials sponsored by Luminary are registered: NCT05312801 in B-cell non-Hodgkin lymphoma with Case Comprehensive Cancer Center, and NCT05546723 in relapsed or refractory multiple myeloma with Cleveland Clinic and Case Western Reserve University. No results have been published.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov: NCT05312801","url":"https://clinicaltrials.gov/study/NCT05312801"},{"label":"ClinicalTrials.gov: NCT05546723","url":"https://clinicaltrials.gov/study/NCT05546723"},{"label":"Luminary Therapeutics: pipeline","url":"https://www.luminarytx.com/pipeline/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":["luminary-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"LMY-920","modality":"Autologous CAR-T cell therapy (BAFF ligand-based CAR)","mechanism":"T cells carry a chimeric antigen receptor built on the BAFF ligand, so each cell can bind three BAFF receptors on malignant B cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lmy-920/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"company":[{"id":"luminary-therapeutics","kind":"company","name":"Luminary Therapeutics","route":"/companies/luminary-therapeutics/"}]}}